Physiological and pathological role of alpha-synuclein in parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element

International Journal of Molecular Sciences

Volumn 10, Issue 3, 2009, Pages 1226-1260

  Olivares, David ^a   Huang, Xudong ^a   Branden, Lars ^b   Greig, Nigel H ^c   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

syn: Alpha synuclein; 5 utr: 5' untranslated region; 6 ohda: 6 hydroxydopamine; Aa: Amino acid(s); Ad: Alzheimer's disease; Cns: Central nervous system; Da: Dopamine; Dat: Dopamine transporter; Dlb: Dementia with lewy bodies; Er: Endoplasmatic reticulum; Gcis: Glial cytoplasmic inclusions; Gsh: Reduced gluthatione; Ire:iron responsive element; Irps: Interacting binding proteins; Lbs: Lewy bodies; Lns: Lewy neurites; Mptp: 1 methyl 4 phenyl 1, 2, 3, 6 tetrapyridine; Nac: Non amyloidogenic component; Nt: Nucleotide(s); Pd: Parkinson's disease; Pld2: Phospholipase d2; Pm: Plasmatic membrane; Ros: Reactive oxygen species; Tfr: Transferrin receptor; Th: Tyrosine hydroxylase; Wt: Wild type

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CAFFEINE; CARBEGOLINE; CARBIDOPA PLUS LEVODOPA; CREATINE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ESTRADIOL; GANGLIOSIDE GM1; GPI 1485; LEVODOPA; LISURIDE; ORPHENADRINE; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; PROFENAMINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ANXIETY; BLADDER DYSFUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRY EYE; DYSKINESIA; DYSTONIA; EDEMA; GENE EXPRESSION; GENE MUTATION; GLAUCOMA; HALLUCINATION; HUMAN; HYPOTENSION; INSOMNIA; IRON RESPONSIVE ELEMENT; LEWY BODY; LIVER TOXICITY; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NITRATION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL EDEMA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PSYCHOSIS; REVIEW; RNA SEQUENCE; SIDE EFFECT; SLEEP DISORDER; TREMOR; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; URINE COLOR; URINE RETENTION; XEROSTOMIA;

Α-SYN: ALPHA-SYNUCLEIN; 5-UTR: 5'-UNTRANSLATED REGION; 6-OHDA: 6-HYDROXYDOPAMINE; AA: AMINO ACID(S); AD: ALZHEIMER'S DISEASE; CNS: CENTRAL NERVOUS SYSTEM; DA: DOPAMINE; DAT: DOPAMINE TRANSPORTER; DLB: DEMENTIA WITH LEWY BODIES; ER: ENDOPLASMATIC RETICULUM; GCIS: GLIAL CYTOPLASMIC INCLUSIONS; GSH: REDUCED GLUTHATIONE; IRE: IRON RESPONSIVE ELEMENT; IRPS: INTERACTING BINDING PROTEINS; LBS: LEWY BODIES; LNS: LEWY NEURITES; MPTP: 1-METHYL 4-PHENYL 1, 2, 3, 6 TETRAPYRIDINE; NAC: NON-AMYLOIDOGENIC COMPONENT; NT: NUCLEOTIDE(S); PD: PARKINSON'S DISEASE; PLD2: PHOSPHOLIPASE D2; PM: PLASMATIC MEMBRANE; ROS: REACTIVE OXYGEN SPECIES; TFR: TRANSFERRIN RECEPTOR; TH: TYROSINE HYDROXYLASE; WT: WILD-TYPE;

ALPHA-SYNUCLEIN; ANIMALS; FERRIC COMPOUNDS; HUMANS; LEVODOPA; LEWY BODIES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA;

EID: 63449129338     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10031226     Document Type: Review

References (186)

1. de Rijk, M.C.; Tzourio, C.; Breteler, M.M.; Dartigues, J.F.; Amaducci, L.; Lopez-Pousa, S.;Manubens-Bertran, J.M.; Alperovitch, A. ; Rocca, W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 1997, 62 (1), 10-15.
2. Guttman, M.; Slaughter, P.M.; Theriault, M.E.; DeBoer, D.P.; Naylor, C.D. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 2001, 57 (12), 2278-2282.
3. Inamdar, N.; Arulmozhi, D.; Tandon, A.; Bodhankar, S. Parkinson's disease: genetics and beyond. Curr. Neuropharmacol. 2007, 5 (2), 99-113.
4. Bennett, M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol. Ther. 2005, 105 (3), 311-331.
5. Forman, M.S.; Lee, V.M. and Trojanowski, J.Q. Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron 2005, 47 (4), 479-482.
6. Yamamura, Y.; Hattori, N.; Matsumine, H.; Kuzuhara, S.; Mizuno, Y. Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain Dev. 2000, 22 (Suppl 1), S87-S91.
7. Lee, V.M. ; Trojanowski, J.Q. Mechanisms of Parkinson's disease linked to pathological alphasynuclein:new targets for drug discovery. Neuron 2006, 52 (1), 33-38.
8. Miyasaki, J.M.; Martin, W.; Suchowersky, O.; Weiner, W.J.; Lang, A.E. Practice parameter:initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58 (1), 11-17.
9. Mercuri, N.B.; Bernardi, G. The 'magic' of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 2005, 26 (7), 341-344.
10. Guttman, M.; Kish, S.J.; Furukawa, Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003, 168 (3), 293-301.
11. Verhagen Metman, L.; Del Dotto, P.; van den Munckhof, P.; Fang, J.; Mouradian, M.M.; Chase, T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50 (5), 1323-1326. 12. Quinn, N.; Parkes, D.; Janota, I.; Marsden, C. D. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov. Disord. 1986, 1 (1), 65-68.
12. Rajput, A.H.; Fenton, M.; Birdi, S.; Macaulay, R. Is levodopa toxic to human substantia nigra? Mov. Disord. 1997, 12 (5), 634-638.
13. Ludin, H.P. [Long-term therapy of the Parkinson syndrome]. Schweiz. Med. Wochenschr. 1984, 114 (33), 1131-1136.
14. Stern, M.B. The early treatment of Parkinson's disease: levodopa, dopamine agonists or both. Parkinsonism Relat. Disord. 2000, 7 (1), 27-33.
15. Weiner, W.J.; Factor, S.A.; Sanchez-Ramos, J.R.; Singer, C.; Sheldon, C.; Cornelius, L.; Ingenito, A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993, 43 (1), 21-27.
16. Rascol, O.; Brooks, D.J.; Korczyn, A.D.; De Deyn, P.P.; Clarke, C.E.; Lang, A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 2000, 342 (20), 1484-1491.
17. Carvey, P.M.; Pieri, S.; Ling, Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J. Neural Transm. 1997, 104 (2-3), 209-28.
18. Clow, A.; Freestone, C.; Lewis, E.; Dexter, D.; Sandler, M.; Glover, V. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci. Lett. 1993, 164 (1-2), 41-43.
19. Felten, D.L.; Felten, S.Y.; Fuller, R.W.; Romano, T.D.; Smalstig, E.B.; Wong, D.T.; Clemens, J.A. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol. Aging 1992, 13 (2), 339-351.
20. Ogawa, N.; Tanaka, K.; Asanuma, M.; Kawai, M.; Masumizu, T.; Kohno, M. and Mori, A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 1994, 657 (1-2), 207-213.
21. Leegwater-Kim, J.; Waters, C. Role of tolcapone in the treatment of Parkinson's disease. Expert Rev. Neurother. 2007, 7 (12), 1649-1657.
22. Arnold, G.; Kupsch, A. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Nervenarzt. 2000, 71 (2), 78-83.
23. Ravina, B.M.; Fagan, S.C.; Hart, R.G.; Hovinga, C.A.; Murphy, D.D.; Dawson, T.M.; Marler, J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60 (8), 1234-1240.
24. Gomez-Tortosa, E.; Newell, K.; Irizarry, M.C.; Albert, M.; Growdon, J.H.; Hyman, B. T. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999, 53 (6), 1284-1291.
25. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95 (11), 6469-6473.
26. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alphasynuclein in Lewy bodies. Nature 1997, 388 (6645), 839-840.
27. Duda, J.E.; Lee, V.M.; Trojanowski, J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61 (2), 121-127. 29. Polymeropoulos, M.H. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann. Neurol. 1998, 44 (Suppl 1), S63-S64.
28. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276 (5321), 2045-2047.
29. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18 (2), 106-108.
30. Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Munoz, D.G. ; de Yebenes, J. G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55 (2), 164-173.
31. Brandis, K.A.; Holmes, I.F.; England, S.J.; Sharma, N.; Kukreja, L.; DebBurman, S.K. alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity. J. Mol. Neurosci. 2006, 28 (2), 179-191.
32. Conway, K.A.; Harper, J.D., Lansbury, P.T., Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39 (10), 2552-2563.
33. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E. and Lansbury, P.T., Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 2000, 97 (2), 571-576.
34. Kotzbauer, P.T.; Giasson, B.I.; Kravitz, A.V.; Golbe, L.I.; Mark, M.H.; Trojanowski, J.Q.; Lee, V.M. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp. Neurol. 2004, 187(2), 279-288.
35. Winkler, S.; Hagenah, J.; Lincoln, S.; Heckman, M.; Haugarvoll, K.; Lohmann-Hedrich, K.; Kostic, V.; Farrer, M. and Klein, C. alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007, 69 (18), 1745-1750.
36. Kobayashi, H.; Ujike, H.; Hasegawa, J.; Yamamoto, M.; Kanzaki, A. and Sora, I. Identification of a risk haplotype of the alpha-synuclein gene in Japanese with sporadic Parkinson's disease. Mov. Disord. 2006, 21 (12), 2157-2164.
37. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302 (5646), 841.
38. Savitt, J.M.; Dawson, V.L.; Dawson, T.M. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J. Clin. Invest. 2006, 116 (7), 1744-1754.
39. Dawson, T.; Mandir, A.; Lee, M. Animal models of PD: Pieces of the same puzzle? Neuron 2002, 35 (2), 219-222. 42. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W.H.; Castillo, P.E.; Shinsky, N.; Verdugo, J.M.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D. and Rosenthal, A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25 (1), 239-252.
40. El-Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Cooper, L.J.; Fullwood, N.J.; Gibson, M.J.; Curran, M.D.; Court, J.A.; Mann, D.M.; Ikeda, S.; Cookson, M.R.; Hardy, J.; Allsop, D. Alphasynuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17 (13), 1945-1947.
41. El-Agnaf, O.M.; Salem, S.A.; Paleologou, K.E.; Curran, M.D.; Gibson, M.J.; Court, J.A.; Schlossmacher, M.G.; Allsop, D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20 (3), 419-425.
42. von Bohlen Und Halbach, O. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 2004, 318 (1), 163-174.
43. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14 (2), 467-475.
44. Nakajo, S.; Shioda, S.; Nakai, Y.; Nakaya, K. Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res. Mol. Brain Res. 1994, 27 (1), 81-86.
45. Lavedan, C. The synuclein family. Genome Res. 1998, 8 (9), 871-80.
46. Eliezer, D.; Kutluay, E.; Bussell, R., Jr.; Browne, G. Conformational properties of alphasynuclein in its free and lipid-associated states. J. Mol. Biol. 2001, 307 (4), 1061-1073.
47. Li, J.; Uversky, V.N. and Fink, A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001, 40 (38), 11604-11613.
48. Fiebig, K.M.; Rice, L.M.; Pollock, E.; Brunger, A.T. Folding intermediates of SNARE complex assembly. Nat. Struct. Biol. 1999, 6 (2), 117-123.
49. George, J.M. The synucleins. Genome Biol. 2002, 3 (1), Reviews3002.
50. Kahle, P.J.; Haass, C.; Kretzschmar, H.A., Neumann, M. Structure/function of alpha-synuclein in health and disease: Rational development of animal models for Parkinson's and related diseases. J. Neurochem. 2002, 82 (3), 449-457.
51. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273 (16), 9443-9449.
52. Lee, H. J.; Choi, C. and Lee, S. J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 2002, 277(1), 671-678.
53. Bussell, R., Jr.; Eliezer, D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 2003, 329 (4), 763-778.
54. Ueda, K.; Fukushima, H.; Masliah, E.; Xia, Y.; Iwai, A.; Yoshimoto, M.; Otero, D. A.; Kondo, J.; Ihara, Y.; Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90 (23), 11282-11286. 58. el-Agnaf, O.M.; Irvine, G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 2002, 30 (4), 559-565.
55. Han, H.; Weinreb, P.H.; Lansbury, P.T., Jr. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: Is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 1995, 2 (3), 163-169.
56. El-Agnaf, O.M.; Jakes, R.; Curran, M.D.; Middleton, D.; Ingenito, R.; Bianchi, E.; Pessi, A.; Neill, D.; Wallace, A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998, 440 (1-2), 71-75.
57. Negro, A.; Brunati, A.M.; Donella-Deana, A.; Massimino, M.L.; Pinna, L.A. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 2002, 16 (2), 210-212.
58. Kim, T.D.; Paik, S.R.; Yang, C.H. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 2002, 41 (46), 13782-13790.
59. Ostrerova, N.; Petrucelli, L.; Farrer, M.; Mehta, N.; Choi, P.; Hardy, J.; Wolozin, B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 1999, 19 (14), 5782-5791.
60. Yuan, J.; Yankner, B.A. Apoptosis in the nervous system. Nature 2000, 407 (6805), 802-809.
61. Xu, J.; Kao, S.Y.; Lee, F.J.; Song, W.; Jin, L.W.; Yankner, B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8 (6), 600-606.
62. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22 (8), 3090-3099.
63. Beyer, K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006, 112 (3), 237-251.
64. Krantz, D.E.; Peter, D.; Liu, Y.; Edwards, R.H. Phosphorylation of a vesicular monoamine transporter by casein kinase II. J. Biol. Chem. 1997, 272 (10), 6752-6759.
65. Pronin, A.N.; Morris, A.J.; Surguchov, A.; Benovic, J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 2000, 275 (34), 26515-26522.
66. Chen, L.; Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8 (5), 657-663.
67. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4 (2), 160-164.
68. Smith, W.W.; Margolis, R.L.; Li, X.; Troncoso, J.C.; Lee, M.K.; Dawson, V.L.; Dawson, T.M.; Iwatsubo, T. and Ross, C.A. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 2005, 25 (23), 5544-5552.
69. Yamada, M.; Iwatsubo, T.; Mizuno, Y. and Mochizuki, H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 2004, 91 (2), 451-461. 74. Souza, J.M.; Giasson, B.I.; Chen, Q.; Lee, V.M.; Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275 (24), 18344-18349.
70. Hodara, R.; Norris, E.H.; Giasson, B.I.; Mishizen-Eberz, A.J.; Lynch, D.R.; Lee, V.M.; Ischiropoulos, H. Functional consequences of alpha-synuclein tyrosine nitration: Diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 2004, 279 (46),47746-47753.
71. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions. Science 2000, 290 (5493), 985-989.
72. Takahashi, T.; Yamashita, H.; Nakamura, T.; Nagano, Y.; Nakamura, S. Tyrosine 125 of alphasynuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002, 938 (1-2), 73-80.
73. Shimura, H.; Schlossmacher, M.G.; Hattori, N.; Frosch, M.P.; Trockenbacher, A.; Schneider, R.; Mizuno, Y.; Kosik, K.S.; Selkoe, D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 2001, 293 (5528), 263-269.
74. Tofaris, G.K.; Layfield, R.; Spillantini, M.G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001, 509 (1), 22-26.
75. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E.; Harta, G.; Brownstein, M.J.; Jonnalagada, S.; Chernova, T.; Dehejia, A.; Lavedan, C.; Gasser, T.; Steinbach, P.J.; Wilkinson, K. D.; Polymeropoulos, M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395 (6701), 451-452.
76. Sampathu, D.M.; Giasson, B.I.; Pawlyk, A.C.; Trojanowski, J.Q.; Lee, V.M. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alphasynucleinopathies. Am. J. Pathol. 2003, 163 (1), 91-100.
77. Lim, K.L.; Dawson, V.L.; Dawson, T.M. The cast of molecular characters in Parkinson's disease: Felons, conspirators, and suspects. Ann. N. Y. Acad. Sci. 2003, 99, 80-92.
78. Rechsteiner, M.; Rogers, S.W. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 1996, 21 (7), 267-271.
79. Beyer, K.; Domingo-Sabat, M.; Lao, J.I.; Carrato, C.; Ferrer, I.; Ariza, A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9 (1), 15-23.
80. Perrin, R.J.; Woods, W.S.; Clayton, D.F. and George, J.M. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 2000, 275 (44), 34393-34398.
81. Crowther, R.A.; Jakes, R.; Spillantini, M.G.; Goedert, M. Synthetic filaments assembled from Cterminally truncated alpha-synuclein. FEBS Lett. 1998, 436 (3), 309-312.
82. Beyer, K.; Lao, J.I.; Carrato, C.; Mate, J.L.; Lopez, D.; Ferrer, I.; Ariza, A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 2004, 30 (6), 601-607. 88. McLean, P.J.; Kawamata, H.; Ribich, S.; Hyman, B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 2000, 275 (12), 8812-8816.
83. Scherzer, C.R.; Jensen, R.V.; Gullans, S.R.; Feany, M.B. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 2003, 12 (19), 2457-2466.
84. Sharon, R.; Bar-Joseph, I.; Frosch, M.P.; Walsh, D.M.; Hamilton, J.A.; Selkoe, D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37 (4), 583-595.
85. Cooper, A.A.; Gitler, A.D.; Cashikar, A.; Haynes, C.M.; Hill, K.J.; Bhullar, B.; Liu, K.; Xu, K.; Strathearn, K.E.; Liu, F.; Cao, S.; Caldwell, K.A.; Caldwell, G.A.; Marsischky, G.; Kolodner, R.D.; Labaer, J.; Rochet, J.C.; Bonini, N.M.; Lindquist, S. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313 (5785), 324-328.
86. Larsen, K.E.; Schmitz, Y.; Troyer, M.D.; Mosharov, E.; Dietrich, P.; Quazi, A.Z.; Savalle, M.; Nemani, V.; Chaudhry, F.A.; Edwards, R.H.; Stefanis, L.; Sulzer, D. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26 (46), 11915-11922.
87. Dev, K.K.; Hofele, K.; Barbieri, S.; Buchman, V.L.; van der Putten, H. Part II: alpha-Synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45 (1), 14-44.
88. Jenco, J.M.; Rawlingson, A.; Daniels, B.; Morris, A.J. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 1998, 37 (14), 4901-4909.
89. Chen, Y.G.; Siddhanta, A.; Austin, C.D.; Hammond, S.M.; Sung, T.C.; Frohman, M.A.; Morris, A.J.; Shields, D. Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. J. Cell Biol. 1997, 138 (3), 495-504.
90. Chandra, S.; Gallardo, G.; Fernandez-Chacon, R.; Schluter, O.M.; Sudhof, T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123 (3), 383-396.
91. Dolgikh, D.A.; Gilmanshin, R.I.; Brazhnikov, E.V.; Bychkova, V.E.; Semisotnov, G.V.; Venyaminov, S.; Ptitsyn, O.B. Alpha-Lactalbumin: Compact state with fluctuating tertiary structure? FEBS Lett. 1981, 136 (2), 311-315.
92. Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276 (47), 44284-44296.
93. Uversky, V.N.; Li, J.; Fink, A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett. 2001, 500 (3), 105-108.
94. Uversky, V.N.; Lee, H.J.; Li, J.; Fink, A.L.; Lee, S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 2001, 276 (47), 43495-43498.
95. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276 (14), 10737-10744. 102. Munishkina, L.A.; Henriques, J.; Uversky, V.N.; Fink, A.L. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry 2004, 43 (11), 3289-3300.
96. Ding, T.T.; Lee, S.J.; Rochet, J.C.; Lansbury, P.T., Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41 (32), 10209-10217.
97. Volles, M.J.; Lansbury, P.T., Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41 (14), 4595-4602.
98. Uversky, V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007, 103 (1), 17-37.
99. Cappai, R.; Leck, S.L.; Tew, D.J.; Williamson, N.A.; Smith, D.P.; Galatis, D.; Sharples, R.A.; Curtain, C.C.; Ali, F.E.; Cherny, R.A.; Culvenor, J.G.; Bottomley, S.P.; Masters, C.L.; Barnham, K.J.; Hill, A.F. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005, 19 (10), 1377-1379.
100. Kowall, N.W.; Hantraye, P.; Brouillet, E.; Beal, M.F.; McKee, A.C.; Ferrante, R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000, 11 (1), 211-213.
101. Krishnan, S.; Chi, E.Y.; Wood, S.J.; Kendrick, B.S.; Li, C.; Garzon-Rodriguez, W.; Wypych, J.; Randolph, T.W.; Narhi, L.O.; Biere, A.L.; Citron, M.; Carpenter, J.F. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 2003, 42 (3), 829-837.
102. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38 (3), 357-366.
103. Stadtman, E.R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 1993, 62, 797-821.
104. Uversky, V.N.; Yamin, G.; Souillac, P.O.; Goers, J.; Glaser, C.B.; Fink, A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 2002, 517 (1-3), 239-244.
105. Jones, D.C.; Gunasekar, P.G.; Borowitz, J.L.; Isom, G.E. Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J. Neurochem. 2000, 74 (6), 2296-2304.
106. Junn, E.; Mouradian, M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 2002, 320 (3), 146-150.
107. Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T., Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294 (5545), 1346-1349.
108. Youdim, M.B. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease? J. Neural. Transm. Suppl. 2003, 65, 73-88.
109. Sidhu, A.; Wersinger, C.; Vernier, P. alpha-Synuclein regulation of the dopaminergic transporter: A possible role in the pathogenesis of Parkinson's disease. FEBS Lett. 2004, 565 (1-3), 1-5. 117. Kaur, D.; Andersen, J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev. 2004, 3 (3), 327-343.
110. Thiruchelvam, M.; Prokopenko, O.; Cory-Slechta, D.A.; Buckley, B.; Mirochnitchenko, O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J. Biol. Chem. 2005, 280 (23), 22530-22539.
111. Wersinger, C.; Prou, D.; Vernier, P.; Sidhu, A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 2003, 17 (14), 2151-2153.
112. Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A.C.; Goodchild, R.; Larsen, K.E.; Staal, R.; Tieu, K.; Schmitz, Y.; Yuan, C.A.; Rocha, M.; Jackson-Lewis, V.; Hersch, S.; Sulzer, D.; Przedborski, S.; Burke, R.; Hen, R. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 2002, 99 (22), 14524-14529.
113. Multhaup, G. Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie 1994, 76 (3-4), 304-311.
114. Cohlberg, J.A.; Li, J.; Uversky, V.N.; Fink, A.L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 2002, 41 (5), 1502-1511.
115. Liu, I.H.; Uversky, V.N.; Munishkina, L.A.; Fink, A.L.; Halfter, W.; Cole, G.J. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology 2005, 15 (12), 1320-1331.
116. Goers, J.; Uversky, V.N.; Fink, A.L. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein. Sci. 2003, 12 (4), 702-707.
117. Manning-Bog, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277 (3), 1641-1644.
118. Andringa, G.; Lam, K.Y.; Chegary, M.; Wang, X.; Chase, T.N. and Bennett, M.C. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 2004, 18 (7), 932-934.
119. Junn, E.; Ronchetti, R.D.; Quezado, M.M.; Kim, S.Y.; Mouradian, M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 2003, 100 (4), 2047-2052.
120. Citron, B.A.; Suo, Z.; SantaCruz, K.; Davies, P.J.; Qin, F.; Festoff, B.W. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem. Int. 2002, 40 (1), 69-78.
121. Jo, E.; McLaurin, J.; Yip, C.M.; St George-Hyslop, P.; Fraser, P.E. alpha-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 2000, 275 (44), 34328-33434.
122. Giasson, B.I.; Uryu, K.; Trojanowski, J.Q.; Lee, V.M. Mutant and wild type human alphasynucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 1999, 274 (12), 7619-7622. 131. Lindersson, E.; Lundvig, D.; Petersen, C.; Madsen, P.; Nyengaard, J.R.; Hojrup, P.; Moos, T.; Otzen, D.; Gai, W.P.; Blumbergs, P.C.; Jensen, P.H. p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J. Biol. Chem. 2005, 280 (7),5703-5715.
123. Lundvig, D.; Lindersson, E. and Jensen, P. H. Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res. 2005, 134 (1), 3-17.
124. Alim, M.A.; Hossain, M.S.; Arima, K.; Takeda, K.; Izumiyama, Y.; Nakamura, M.; Kaji, H.; Shinoda, T.; Hisanaga, S.; Ueda, K. Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 2002, 277 (3), 2112-2117.
125. Iwata, A.; Miura, S.; Kanazawa, I.; Sawada, M.; Nukina, N. alpha-Synuclein forms a complex with transcription factor Elk-1. J. Neurochem. 2001, 77 (1), 239-252.
126. Lindersson, E.K.; Hojrup, P.; Gai, W.P.; Locker, D.; Martin, D.; Jensen, P.H. alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 2004, 15 (18), 2735-2739.
127. McLean, P.J.; Kawamata, H.; Shariff, S.; Hewett, J.; Sharma, N.; Ueda, K.; Breakefield, X.O.; Hyman, B.T. TorsinA and heat shock proteins act as molecular chaperones: Suppression of alpha-synuclein aggregation. J. Neurochem. 2002, 83 (4), 846-854.
128. Clayton, D.F.; George, J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 1999, 58 (1), 120-129.
129. Uversky, V.N.; Li, J.; Souillac, P.; Millett, I.S.; Doniach, S.; Jakes, R.; Goedert, M.; Fink, A.L. Biophysical properties of the synucleins and their propensities to fibrillate: Inhibition of alphasynuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 2002, 277 (14), 11970-11978.
130. Yamin, G.; Munishkina, L.A.; Karymov, M.A.; Lyubchenko, Y.L.; Uversky, V.N.; Fink, A.L. Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry 2005, 44 (25), 9096-9107.
131. Hashimoto, M.; Rockenstein, E.; Mante, M.; Mallory, M.; Masliah, E. beta-Synuclein inhibits alpha-synuclein aggregation: A possible role as an anti-parkinsonian factor. Neuron 2001, 32 (2), 213-223.
132. Saito, Y.; Kawashima, A.; Ruberu, N.N.; Fujiwara, H.; Koyama, S.; Sawabe, M.; Arai, T.; Nagura, H.; Yamanouchi, H.; Hasegawa, M.; Iwatsubo, T.; Murayama, S. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 2003, 62 (6), 644-654.
133. Ii, K.; Ito, H.; Tanaka, K.; Hirano, A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 1997, 56 (2), 125-131.
134. Lindersson, E.; Beedholm, R.; Hojrup, P.; Moos, T.; Gai, W.; Hendil, K.B.; Jensen, P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279 (13), 12924-12934.
135. Recchia, A.; Debetto, P.; Negro, A.; Guidolin, D.; Skaper, S.D.; Giusti, P. Alpha-synuclein and Parkinson's disease. FASEB J. 2004, 18 (6), 617-626.
136. Klucken, J.; Shin, Y.; Masliah, E.; Hyman, B.T.; McLean, P.J. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J. Biol. Chem. 2004, 279 (24), 25497-25502. 146. Paleologou, K.E.; Irvine, G.B.; El-Agnaf, O.M. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans. 2005, 33 (Pt 5), 1106-1110.
137. Hirsch, E.C.; Brandel, J.P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis. J. Neurochem. 1991, 56 (2), 446-451.
138. Sofic, E.; Riederer, P.; Heinsen, H.; Beckmann, H.; Reynolds, G.P.; Hebenstreit, G.; Youdim, M. B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 1988, 74 (3), 199-205.
139. Paik, S.R.; Shin, H.J. and Lee, J.H. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 2000, 378 (2), 269-277.
140. Paik, S.R.; Lee, J.H.; Kim, D.H.; Chang, C.S.; Kim, J. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Arch. Biochem. Biophys. 1997, 344 (2), 325-334.
141. Brown, D.R. Interactions between metals and alpha-synuclein-function or artefact? FEBS J. 2007, 274 (15), 3766-3774.
142. Yamin, G.; Glaser, C.B.; Uversky, V.N. and Fink, A.L. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J. Biol. Chem. 2003, 278 (30), 27630-27635.
143. Ostrerova-Golts, N.; Petrucelli, L.; Hardy, J.; Lee, J.M.; Farer, M.; Wolozin, B. The A53T alphasynuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 2000, 20 (16), 6048-6054.
144. Chiba-Falek, O.; Lopez, G.J.; Nussbaum, R.L. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 2006, 21 (10), 1703-1708.
145. Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157 (2), 401-410.
146. Stefanis, L.; Larsen, K.E.; Rideout, H.J.; Sulzer, D.; Greene, L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21 (24), 9549-9560.
147. Gosavi, N.; Lee, H.J.; Lee, J.S.; Patel, S.; Lee, S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 2002, 277 (50), 48984-48992.
148. Lo Bianco, C.; Ridet, J.L.; Schneider, B.L.; Deglon, N.; Aebischer, P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2002, 99 (16), 10813-10818.
149. Rockenstein, E.; Hansen, L.A.; Mallory, M.; Trojanowski, J.Q.; Galasko, D.; Masliah, E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 2001, 914 (1-2), 48-56.
150. Vila, M.; Vukosavic, S.; Jackson-Lewis, V.; Neystat, M.; Jakowec, M.; Przedborski, S. Alphasynuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74 (2), 721-729. 161. Talpade, D.J.; Greene, J.G.; Higgins, D.S., Jr.; Greenamyre, J.T. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J. Neurochem. 2000, 75 (6), 2611-2621.
151. Greenamyre, J.T.; Hastings, T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004, 304 (5674), 1120-1122.
152. Seo, J.H.; Rah, J.C.; Choi, S.H.; Shin, J.K.; Min, K.; Kim, H.S.; Park, C.H.; Kim, S.; Kim, E.M.; Lee, S.H.; Lee, S.; Suh, S.W.; Suh, Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2002, 16 (13), 1826-1828.
153. Pezzella, A.; d'Ischia, M.; Napolitano, A.; Misuraca, G.; Prota, G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 1997, 40 (14), 2211-2216.
154. Jellinger, K.; Paulus, W.; Grundke-Iqbal, I.; Riederer, P.; Youdim, M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Park. Dis. Dement. Sect. 1990, 2 (4), 327-340.
155. Sayre, L.M.; Moreira, P.I.; Smith, M.A.; Perry, G. Metal ions and oxidative protein modification in neurological disease. Ann. Ist. Super. Sanita. 2005, 41 (2), 143-164.
156. Kaur, D.; Andersen, J.K. Ironing out Parkinson's disease: Is therapeutic treatment with iron chelators a real possibility? Aging Cell 2002, 1 (1), 17-21.
157. Andersen, J.K. Iron dysregulation and Parkinson's disease. J. Alzheimers. Dis. 2004, 6 (Suppl 6), S47-S52.
158. Theil, E.C.; Eisenstein, R.S. Combinatorial mRNA regulation: Iron regulatory proteins and isoiron-responsive elements (Iso-IREs). J. Biol. Chem. 2000, 275 (52), 40659-40662.
159. Cairo, G.; Pietrangelo, A. Iron regulatory proteins in pathobiology. Biochem. J. 2000, 352 (Pt 2), 241-250.
160. Youdim, M.B.; Ben-Shachar, D.; Riederer, P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur. Neurol. 1991, 31 ( Suppl 1), 34-40.
161. Glinka, Y.; Tipton, K.F.; Youdim, M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J. Neurochem. 1996, 66 (5), 2004-2010.
162. Ben-Shachar, D.; Eshel, G.; Finberg, J.P.; Youdim, M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56 (4), 1441-1444.
163. Grunblatt, E.; Mandel, S.; Berkuzki, T.; Youdim, M.B. Apomorphine protects against MPTPinduced neurotoxicity in mice. Mov. Disord. 1999, 14 (4), 612-618.
164. LaVaute, T.; Smith, S.; Cooperman, S.; Iwai, K.; Land, W.; Meyron-Holtz, E.; Drake, S.K.; Miller, G.; Abu-Asab, M.; Tsokos, M.; Switzer, R., 3rd; Grinberg, A.; Love, P.; Tresser, N. and Rouault, T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 2001, 27 (2), 209-214.
165. Crompton, D.E.; Chinnery, P.F.; Fey, C.; Curtis, A.R.; Morris, C.M.; Kierstan, J.; Burt, A.; Young, F.; Coulthard, A.; Curtis, A.; Ince, P.G.; Bates, D.; Jackson, M.J.; Burn, J. Neuroferritinopathy: A window on the role of iron in neurodegeneration. Blood Cells Mol. Dis. 2002, 29 (3), 522-531.
166. Borie, C.; Gasparini, F.; Verpillat, P.; Bonnet, A.M.; Agid, Y.; Hetet, G.; Brice, A.; Durr, A.; Grandchamp, B. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 2002, 249 (7), 801-804.
167. Balla, G.; Jacob, H.S.; Balla, J.; Rosenberg, M.; Nath, K.; Apple, F.; Eaton, J.W.; Vercellotti, G.M. Ferritin: A cytoprotective antioxidant strategem of endothelium. J. Biol. Chem. 1992, 267 (25), 18148-18153.
168. Kwak, E.L.; Larochelle, D.A.; Beaumont, C.; Torti, S.V.; Torti, F.M. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J. Biol. Chem. 1995, 270 (25), 15285-15293.
169. Martins, E.A.; Robalinho, R.L.; Meneghini, R. Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. Arch. Biochem. Biophys. 1995, 316 (1), 128-134.
170. Nunez, M.T.; Nunez-Millacura, C.; Tapia, V.; Munoz, P.; Mazariegos, D.; Arredondo, M.; Mura, C.; Maccioni, R.B. Iron-activated iron uptake: A positive feedback loop mediated by iron regulatory protein 1. Biometals 2003, 16 (1), 83-90.
171. Faucheux, B.A.; Martin, M.E.; Beaumont, C.; Hunot, S.; Hauw, J.J.; Agid, Y.; Hirsch, E.C. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 2002, 83 (2), 320-330.
172. Lin, E.; Graziano, J.H.; Freyer, G.A. Regulation of the 75-kDa subunit of mitochondrial complex I by iron. J Biol Chem 2001, 276 (29), 27685-27692.
173. Dandekar, T.; Stripecke, R.; Gray, N.K.; Goossen, B.; Constable, A.; Johansson, H.E.; Hentze, M.W. Identification of a novel iron-responsive element in murine and human erythroid deltaaminolevulinic acid synthase mRNA. EMBO J. 1991, 10 (7), 1903-1909.
174. Castellani, R.J.; Siedlak, S.L.; Perry, G.; Smith, M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 2000, 100 (2), 111-114.
175. Friedlich, A.L.; Tanzi, R.E. and Rogers, J.T. The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 2007, 12 (3), 222-223.
176. Xia, Y.; Saitoh, T.; Ueda, K.; Tanaka, S.; Chen, X.; Hashimoto, M.; Hsu, L.; Conrad, C.; Sundsmo, M.; Yoshimoto, M.; Thal, L.; Katzman, R. ; Masliah, E. Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 2001, 3 (5), 485-494.
177. Preiss, T.; Muckenthaler, M.; Hentze, M.W. Poly(A)-tail-promoted translation in yeast: Implications for translational control. RNA 1998, 4 (11), 1321-1331.
178. Bordeleau, M.E.; Matthews, J.; Wojnar, J.M.; Lindqvist, L.; Novac, O.; Jankowsky, E.; Sonenberg, N.; Northcote, P.; Teesdale-Spittle, P.; Pelletier, J. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl. Acad. Sci. USA 2005, 102 (30), 10460-10465.
179. Hundsdoerfer, P.; Thoma, C.; Hentze, M.W. Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation. Proc. Natl. Acad. Sci. USA 2005, 102 (38), 13421-13426. 191. Nie, M.; Htun, H. Different modes and potencies of translational repression by sequence-specific RNA-protein interaction at the 5'-UTR. Nucleic Acids Res. 2006, 34 (19), 5528-5540.
180. Rogers, J.T.; Randall, J.D.; Cahill, C.M.; Eder, P.S.; Huang, X.; Gunshin, H.; Leiter, L.; McPhee, J.; Sarang, S.S.; Utsuki, T.; Greig, N.H.; Lahiri, D.K.; Tanzi, R.E.; Bush, A.I.; Giordano, T.; Gullans, S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277 (47), 45518-45528.
181. Payton, S.; Cahill, C.M.; Randall, J.D.; Gullans, S.R.; Rogers, J.T. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: The action of paroxetine and dimercaptopropanol. J. Mol. Neurosci. 2003, 20 (3), 267-275.
182. Rogers, J.T.; Randall, J.D.; Eder, P.S.; Huang, X.; Bush, A.I.; Tanzi, R.E.; Venti, A.; Payton, S.M.; Giordano, T.; Nagano, S.; Cahill, C.M.; Moir, R.; Lahiri, D.K.; Greig, N.; Sarang, S.S.; Gullans, S.R. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J. Mol. Neurosci. 2002, 19 (1-2), 77-82.
183. Lahiri, D.K.; Chen, D.; Maloney, B.; Holloway, H.W.; Yu, Q.S.; Utsuki, T.; Giordano, T.; Sambamurti, K.; Greig, N.H. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther. 2007, 320 (1), 386-396.
184. Shaw, K.T.; Utsuki, T.; Rogers, J.; Yu, Q.S.; Sambamurti, K.; Brossi, A.; Ge, Y.W.; Lahiri, D.K. ; Greig, N.H. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA 2001, 98 (13), 7605-7610.
185. Scherzer, C.R.; Grass, J.A.; Liao, Z.; Pepivani, I.; Zheng, B.; Eklund, A.C.; Ney, P.A.; Ng, J.; McGoldrick, M.; Mollenhauer, B.; Bresnick, E.H.; Schlossmacher, M.G. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc. Natl. Acad. Sci. USA 2008, 105 (31), 10907-10912.
186. Lippa, C.F.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 1999, 45 (3), 353-357.